## Philippe Ravaud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1564169/publications.pdf

Version: 2024-02-01

378 papers 35,801 citations

93 h-index 176 g-index

399 all docs 399 docs citations

times ranked

399

39926 citing authors

#	Article	IF	CITATIONS
1	A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. European Heart Journal, 2003, 24, 1231-1243.	1.0	2,808
2	Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration. Annals of Internal Medicine, 2008, 148, 295.	2.0	1,865
3	Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery?. European Heart Journal, 2005, 26, 2714-2720.	1.0	966
4	Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. New England Journal of Medicine, 2014, 371, 1771-1780.	13.9	842
5	CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Annals of Internal Medicine, 2017, 167, 40.	2.0	833
6	What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?. European Heart Journal, 2007, 28, 1358-1365.	1.0	763
7	EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2010, 69, 1103-1109.	0.5	734
8	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia. JAMA Internal Medicine, 2021, 181, 32.	2.6	654
9	Comparison of Registered and Published Primary Outcomes in Randomized Controlled Trials. JAMA - Journal of the American Medical Association, 2009, 302, 977.	3.8	620
10	Reporting and Interpretation of Randomized Controlled Trials With Statistically Nonsignificant Results for Primary Outcomes. JAMA - Journal of the American Medical Association, 2010, 303, 2058.	3.8	585
11	High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial. Blood, 1998, 92, 3131-3136.	0.6	498
12	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	3.8	498
13	Methods and Processes of the CONSORT Group: Example of an Extension for Trials Assessing Nonpharmacologic Treatments. Annals of Internal Medicine, 2008, 148, W-60.	2.0	415
14	EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2011, 70, 968-972.	0.5	383
15	Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ, The, 2013, 346, f2304-f2304.	3.0	377
16	Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Cmaj, 2013, 185, E201-E211.	0.9	370
17	Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS). Arthritis and Rheumatism, 2004, 50, 1270-1276.	6.7	368
18	Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 510-519.	4.6	366

#	Article	IF	Citations
19	High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe. Journal of Clinical Oncology, 2005, 23, 9227-9233.	0.8	356
20	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ, The, 2020, 369, m1844.	3.0	355
21	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. Arthritis and Rheumatism, 2010, 62, 2458-2466.	6.7	352
22	Increasing value and reducing waste in biomedical research: who's listening?. Lancet, The, 2016, 387, 1573-1586.	6.3	346
23	Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis <alt-title>Metformin Use With Diabetes and Atherothrombosis</alt-title> . Archives of Internal Medicine, 2010, 170, 1892.	4.3	319
24	Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ: British Medical Journal, 2012, 344, e1119-e1119.	2.4	304
25	A checklist to evaluate a report of a nonpharmacological trial (CLEAR NPT) was developed using consensus. Journal of Clinical Epidemiology, 2005, 58, 1233-1240.	2.4	287
26	Impact of Spin in the Abstracts of Articles Reporting Results of Randomized Controlled Trials in the Field of Cancer: The SPIIN Randomized Controlled Trial. Journal of Clinical Oncology, 2014, 32, 4120-4126.	0.8	281
27	Reporting Methods of Blinding in Randomized Trials Assessing Nonpharmacological Treatments. PLoS Medicine, 2007, 4, e61.	3.9	270
28	Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis and Rheumatism, 2010, 62, 2625-2632.	6.7	266
29	Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Annals of the Rheumatic Diseases, 2011, 70, 616-623.	0.5	249
30	Efficacy and safety of belimumab in primary Sj $\tilde{A}$ $\P$ gren's syndrome: results of the BELISS open-label phase II study. Annals of the Rheumatic Diseases, 2015, 74, 526-531.	0.5	248
31	Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome. JAMA - Journal of the American Medical Association, 2014, 312, 249.	3.8	241
32	Reporting of Safety Results in Published Reports of Randomized Controlled Trials. Archives of Internal Medicine, 2009, 169, 1756.	4.3	230
33	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. RMD Open, 2015, 1, e000022-e000022.	1.8	229
34	Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials. Journal of Clinical Epidemiology, 2004, 57, 543-550.	2.4	228
35	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Annals of the Rheumatic Diseases, 2016, 75, 382-389.	0.5	225
36	Single-Center Trials Show Larger Treatment Effects Than Multicenter Trials: Evidence From a Meta-epidemiologic Study. Annals of Internal Medicine, 2011, 155, 39.	2.0	224

#	Article	IF	CITATIONS
37	Quality of Reporting of Noninferiority and Equivalence Randomized Trials. JAMA - Journal of the American Medical Association, 2006, 295, 1147.	3.8	218
38	Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Annals of the Rheumatic Diseases, 2014, 73, 2074-2081.	0.5	204
39	Comparison of Clinical Presentations and Outcomes Between Patients With <i>TGFBR2</i> and <i>FBN1</i> Mutations in Marfan Syndrome and Related Disorders. Circulation, 2009, 120, 2541-2549.	1.6	203
40	Reporting of sample size calculation in randomised controlled trials: review. BMJ: British Medical Journal, 2009, 338, b1732-b1732.	2.4	201
41	Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: Results of a multicenter, randomized, controlled trial. Arthritis and Rheumatism, 1999, 42, 475-482.	6.7	196
42	Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Annals of the Rheumatic Diseases, 2013, 72, 1026-1031.	0.5	193
43	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Annals of the Rheumatic Diseases, 2015, 74, 859-866.	0.5	193
44	Misrepresentation of Randomized Controlled Trials in Press Releases and News Coverage: A Cohort Study. PLoS Medicine, 2012, 9, e1001308.	3.9	192
45	Timing and Completeness of Trial Results Posted at ClinicalTrials.gov and Published in Journals. PLoS Medicine, 2013, 10, e1001566.	3.9	191
46	Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Annals of the Rheumatic Diseases, 2010, 69, 400-408.	0.5	190
47	Comparison of Treatment Effect Estimates From Prospective Nonrandomized Studies With Propensity Score Analysis and Randomized Controlled Trials of Surgical Procedures. Annals of Surgery, 2014, 259, 18-25.	2.1	190
48	Development and description of measurement properties of an instrument to assess treatment burden among patients with multiple chronic conditions. BMC Medicine, 2012, 10, 68.	2.3	186
49	Effect of editors' implementation of CONSORT guidelines on the reporting of abstracts in high impact medical journals: interrupted time series analysis. BMJ, The, 2012, 344, e4178-e4178.	3.0	178
50	Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques. Stroke, 2014, 45, 1248-1257.	1.0	178
51	Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data. Lancet, The, 2008, 371, 744-751.	6.3	173
52	Feeling good rather than feeling better matters more to patients. Arthritis and Rheumatism, 2006, 55, 526-530.	6.7	167
53	Misrepresentation and distortion of research in biomedical literature. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2613-2619.	3.3	166
54	Adaptation and validation of the Treatment Burden Questionnaire (TBQ) in English using an internet platform. BMC Medicine, 2014, 12, 109.	2.3	163

#	Article	IF	CITATIONS
55	The ESPOIR cohort: A ten-year follow-up of early arthritis in France. Joint Bone Spine, 2007, 74, 440-445.	0.8	161
56	Association Between Analytic Strategy and Estimates of Treatment Outcomes in Meta-analyses. JAMA - Journal of the American Medical Association, 2014, 312, 623.	3.8	161
57	Nonâ€"TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug. JAMA - Journal of the American Medical Association, 2016, 316, 1172.	3.8	160
58	Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology, 2011, 50, 222-229.	0.9	159
59	The Burden of Musculoskeletal Conditions. PLoS ONE, 2014, 9, e90633.	1.1	159
60	Taxonomy of the burden of treatment: a multi-country web-based qualitative study of patients with chronic conditions. BMC Medicine, 2015, 13, 115.	2.3	158
61	Reporting of results from network meta-analyses: methodological systematic review. BMJ, The, 2014, 348, g1741-g1741.	3.0	149
62	Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren's Syndrome. Data at Enrollment in the Prospective ASSESS Cohort. PLoS ONE, 2013, 8, e59868.	1.1	147
63	Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. BMJ, The, 2020, 368, l6802.	3.0	143
64	Patients' views of wearable devices and AI in healthcare: findings from the ComPaRe e-cohort. Npj Digital Medicine, 2019, 2, 53.	5.7	140
65	Methodological Differences in Clinical Trials Evaluating Nonpharmacological and Pharmacological Treatments of Hip and Knee Osteoarthritis. JAMA - Journal of the American Medical Association, 2003, 290, 1062.	3.8	138
66	Management of nontuberculous infectious discitis. Treatments used in 110 patients admitted to 12 teaching hospitals in France. Joint Bone Spine, 2001, 68, 504-509.	0.8	133
67	Impact of interventions to improve the quality of peer review of biomedical journals: a systematic review and meta-analysis. BMC Medicine, 2016, 14, 85.	2.3	131
68	Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). Annals of the Rheumatic Diseases, 2015, 74, 1725-1733.	0.5	130
69	Determinants of satisfaction 1Âyear after total hip arthroplasty: the role of expectations fulfilment. BMC Musculoskeletal Disorders, 2014, 15, 53.	0.8	129
70	A new classification of spin in systematic reviews and meta-analyses was developed and ranked according to the severity. Journal of Clinical Epidemiology, 2016, 75, 56-65.	2.4	129
71	Maintenance of infliximab treatment in ankylosing spondylitis: Results of a oneâ€year randomized controlled trial comparing systematic versus onâ€demand treatment. Arthritis and Rheumatism, 2008, 58, 88-97.	6.7	126
72	The Reporting of Randomized Clinical Trials Using a Surgical Intervention Is in Need of Immediate Improvement. Annals of Surgery, 2006, 244, 677-683.	2.1	125

#	Article	IF	Citations
73	Underrepresentation of Elderly People in Randomised Controlled Trials. The Example of Trials of 4 Widely Prescribed Drugs. PLoS ONE, 2012, 7, e33559.	1.1	125
74	Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. Aids, 2007, 21, 1457-1465.	1.0	124
75	Clinical research activity in periodontal medicine: a systematic mapping of trial registers. Journal of Clinical Periodontology, 2016, 43, 390-400.	2.3	123
76	Preventing Bias in Cluster Randomised Trials. PLoS Medicine, 2009, 6, e1000065.	3.9	121
77	Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. Autoimmunity Reviews, 2015, 14, 1154-1160.	2.5	121
78	Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. European Heart Journal, 2010, 31, 1257-1265.	1.0	119
79	Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the †Orencia and Rheumatoid Arthritis' registry. Annals of the Rheumatic Diseases, 2012, 71, 1815-1819.	0.5	117
80	Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study. BMJ: British Medical Journal, 2017, 357, j2490.	2.4	114
81	Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. Journal of Rheumatology, 2007, 34, 1188-93.	1.0	114
82	Methods of Blinding in Reports of Randomized Controlled Trials Assessing Pharmacologic Treatments: A Systematic Review. PLoS Medicine, 2006, 3, e425.	3.9	113
83	Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. Aids, 2004, 18, 1429-1433.	1.0	112
84	The Volume-Outcome Relationship in Critical Care. Chest, 2015, 148, 79-92.	0.4	112
85	Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19. JAMA Internal Medicine, 2021, 181, 1241.	2.6	111
86	Determinants of the Survival Benefit of Lung Transplantation in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1156-1163.	2.5	110
87	Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry. Annals of the Rheumatic Diseases, 2012, 71, 84-87.	0.5	109
88	Effect of hyaluronic acid in symptomatic hip osteoarthritis: A multicenter, randomized, placeboâ€controlled trial. Arthritis and Rheumatism, 2009, 60, 824-830.	6.7	106
89	Avoidable waste of research related to inadequate methods in clinical trials. BMJ, The, 2015, 350, h809-h809.	3.0	106
90	Interleukin-6 blocking agents for treating COVID-19: a living systematic review. The Cochrane Library, 2021, 2021, CD013881.	1.5	106

#	Article	IF	CITATIONS
91	Identifying outcomes for depression that matter to patients, informal caregivers, and health-care professionals: qualitative content analysis of a large international online survey. Lancet Psychiatry,the, 2020, 7, 692-702.	3.7	103
92	Longâ€Term Outcomes Among Participants in the WEGENT Trial of Remissionâ€Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. Arthritis and Rheumatology, 2016, 68, 690-701.	2.9	101
93	The Influence of Anti-Infective Periodontal Treatment on C-Reactive Protein: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2013, 8, e77441.	1.1	100
94	Mapping of Crowdsourcing in Health: Systematic Review. Journal of Medical Internet Research, 2018, 20, e187.	2.1	100
95	Adjustment for reporting bias in network meta-analysis of antidepressant trials. BMC Medical Research Methodology, 2012, 12, 150.	1.4	99
96	Recommendations of the French Society for Rheumatology regarding TNF $\hat{l}_{\pm}$ antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine, 2007, 74, 638-646.	0.8	98
97	Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis and Rheumatism, 2009, 61, 108-118.	6.7	98
98	Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study. BMJ: British Medical Journal, 2012, 344, e813-e813.	2.4	98
99	Classification and prevalence of spin in abstracts of non-randomized studies evaluating an intervention. BMC Medical Research Methodology, 2015, 15, 85.	1.4	94
100	Observer bias in randomized clinical trials with time-to-event outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. International Journal of Epidemiology, 2014, 43, 937-948.	0.9	93
101	Classification criteria for Sj $\tilde{A}$ ¶gren's syndrome: we actually need to definitively resolve the long debate on the issue. Annals of the Rheumatic Diseases, 2013, 72, 476-478.	0.5	90
102	Methods and Reporting Studies Assessing Fecal Microbiota Transplantation. Annals of Internal Medicine, 2017, 167, 34.	2.0	88
103	Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer. BMC Medicine, 2016, 14, 8.	2.3	87
104	Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles. BMC Medicine, 2015, 13, 189.	2.3	86
105	Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review. BMJ, The, 2013, 347, f3675-f3675.	3.0	85
106	Potential workload in applying clinical practice guidelines for patients with chronic conditions and multimorbidity: a systematic analysis. BMJ Open, 2016, 6, e010119.	0.8	85
107	A review of blinding in randomized controlled trials found results inconsistent and questionable. Journal of Clinical Epidemiology, 2005, 58, 1220-1226.	2.4	83
108	Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Modern Pathology, 2009, 22, 273-281.	2.9	82

#	Article	IF	Citations
109	Meta-analyses including non-randomized studies of therapeutic interventions: a methodological review. BMC Medical Research Methodology, 2016, 16, 35.	1.4	82
110	Impact of searching clinical trial registries in systematic reviews of pharmaceutical treatments: methodological systematic review and reanalysis of meta-analyses. BMJ: British Medical Journal, 2017, 356, j448.	2.4	82
111	Influence of replacing tuberculin skin test with ex vivo interferon $\hat{I}^3$ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Annals of the Rheumatic Diseases, 2012, 71, 1783-1790.	0.5	81
112	Impact of ultrasound imaging on local corticosteroid injections of symptomatic ankle, hind-, and mid-foot in chronic inflammatory diseases. Arthritis and Rheumatism, 2005, 53, 284-292.	6.7	80
113	Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Annals of the Rheumatic Diseases, 2007, 66, 1610-1615.	0.5	80
114	Exclusion of patients with concomitant chronic conditions in ongoing randomised controlled trials targeting 10 common chronic conditions and registered at ClinicalTrials.gov: a systematic review of registration details. BMJ Open, 2016, 6, e012265.	0.8	79
115	A Multistep Voriconazole-Related Phototoxic Pathway May Lead to Skin Carcinoma: Results From a French Nationwide Study. Clinical Infectious Diseases, 2013, 57, e182-e188.	2.9	78
116	Impact of an online writing aid tool for writing a randomized trial report: the COBWEB (Consort-based WEB tool) randomized controlled trial. BMC Medicine, 2015, 13, 221.	2.3	78
117	Outcome measures for primary SjÃ $\P$ gren's syndrome: A comprehensive review. Journal of Autoimmunity, 2014, 51, 51-56.	3.0	77
118	Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ: British Medical Journal, 2019, 364, l67.	2.4	76
119	Lack of Head-to-head Trials and Fair Control Arms. Archives of Internal Medicine, 2012, 172, 237.	4.3	74
120	Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues. Journal of Rheumatology, 2005, 32, 2025-9.	1.0	72
121	European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patientâ∈Reported Index: A Complete Picture of Primary SjÁ¶gren's Syndrome Patients. Arthritis Care and Research, 2013, 65, 1358-1364.	1.5	71
122	Recommendations of the French Society for Rheumatology regarding TNF $\hat{l}_{\pm}$ antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine, 2007, 74, 627-637.	0.8	70
123	A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2008, 67, 478-484.	0.5	70
124	The COVID-NMA Project: Building an Evidence Ecosystem for the COVID-19 Pandemic. Annals of Internal Medicine, 2020, 173, 1015-1017.	2.0	70
125	Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis. Arthritis and Rheumatism, 2006, 55, 960-963.	6.7	68
126	Reviews assessing the quality or the reporting of randomized controlled trials are increasing over time but raised questions about how quality is assessed. Journal of Clinical Epidemiology, 2011, 64, 136-144.	2.4	68

#	Article	IF	Citations
127	Reporting of Adherence to Medication in Recent Randomized Controlled Trials of 6 Chronic Diseases: A Systematic Literature Review. American Journal of the Medical Sciences, 2007, 334, 248-254.	0.4	67
128	The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidence. BMC Medicine, 2020, 18, 6.	2.3	67
129	Development and Validation of the Long Coronavirus Disease (COVID) Symptom and Impact Tools: A Set of Patient-Reported Instruments Constructed From Patients' Lived Experience. Clinical Infectious Diseases, 2022, 74, 278-287.	2.9	67
130	Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. Arthritis Care and Research, 2010, 62, 551-558.	1.5	66
131	Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study. Rheumatology, 2015, 54, kev257.	0.9	66
132	The statistical significance of meta-analyses is frequently fragile: definition of a fragility index for meta-analyses. Journal of Clinical Epidemiology, 2019, 111, 32-40.	2.4	65
133	Prevalence of fibromyalgia in France: a multi-step study research combining national screening and clinical confirmation: The DEFI study (Determination of Epidemiology of Flbromyalgia). BMC Musculoskeletal Disorders, 2011, 12, 224.	0.8	64
134	Reporting quality of studies using machine learning models for medical diagnosis: a systematic review. BMJ Open, 2020, 10, e034568.	0.8	63
135	Comparison of Patient and Surgeon Expectations of Total Hip Arthroplasty. PLoS ONE, 2012, 7, e30195.	1.1	63
136	Validation of a short form of the Western Ontario and McMaster Universities Osteoarthritis Index function subscale in hip and knee osteoarthritis. Arthritis and Rheumatism, 2007, 57, 633-638.	6.7	62
137	Association of Anti– <i>Porphyromonas gingivalis</i> Antibody Titers With Nonsmoking Status in Early Rheumatoid Arthritis: Results From the Prospective French Cohort of Patients With Early Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 1729-1737.	2.9	61
138	Predicting data saturation in qualitative surveys with mathematical models from ecological research. Journal of Clinical Epidemiology, 2017, 82, 71-78.e2.	2.4	61
139	The RATIO observatory: French registry ofÂopportunistic infections, severe bacterial infections, andÂlymphomas complicating anti-TnFî± therapy. Joint Bone Spine, 2005, 72, 456-460.	0.8	60
140	Use of Trial Register Information during the Peer Review Process. PLoS ONE, 2013, 8, e59910.	1.1	60
141	Validation of the Ottawa Ankle Rules in France: A Study in the Surgical Emergency Department of a Teaching Hospital. Annals of Emergency Medicine, 1998, 32, 14-18.	0.3	57
142	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Annals of the Rheumatic Diseases, 2016, 75, 1945-1950.	0.5	57
143	Construction of a questionnaire measuring outpatients' opinion of quality of hospital consultation departments. Health and Quality of Life Outcomes, 2004, 2, 43.	1.0	54
144	Empirical evaluation of which trial characteristics are associated with treatment effect estimates. Journal of Clinical Epidemiology, 2016, 77, 24-37.	2.4	53

#	Article	IF	Citations
145	Personalized Physical Therapy Versus Usual Care for Patients With Systemic Sclerosis: A Randomized Controlled Trial. Arthritis Care and Research, 2017, 69, 1050-1059.	1.5	52
146	Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov. Journal of Clinical Oncology, 2017, 35, 1686-1694.	0.8	52
147	Interpretation of Results of Studies Evaluating an Intervention Highlighted in Google Health News: A Cross-Sectional Study of News. PLoS ONE, 2015, 10, e0140889.	1.1	52
148	Planning a cluster randomized trial with unequal cluster sizes: practical issues involving continuous outcomes. BMC Medical Research Methodology, 2006, 6, 17.	1.4	50
149	Association between trial registration and treatment effect estimates: a meta-epidemiological study. BMC Medicine, 2016, 14, 100.	2.3	50
150	Violation of the intent-to-treat principle and rate of missing data in superiority trials assessing structural outcomes in rheumatic diseases. Arthritis and Rheumatism, 2005, 52, 1858-1865.	6.7	49
151	Recommendations ofÂtheÂFrench Society forÂRheumatology. TNFα antagonist therapy inÂrheumatoid arthritis. Joint Bone Spine, 2006, 73, 433-441.	0.8	49
152	Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry. Rheumatology, 2016, 55, 874-882.	0.9	49
153	Effect of a collective educational program for patients with rheumatoid arthritis: a prospective 12-month randomized controlled trial. Journal of Rheumatology, 2007, 34, 1684-91.	1.0	49
154	Living with HIV, Antiretroviral Treatment Experience and Tobacco Smoking: Results from a Multisite Cross-Sectional Study. Antiviral Therapy, 2008, 13, 389-398.	0.6	49
155	The most important tasks for peer reviewers evaluating a randomized controlled trial are not congruent with the tasks most often requested by journal editors. BMC Medicine, 2015, 13, 158.	2.3	47
156	Reporting of Harm in Randomized, Controlled Trials of Nonpharmacologic Treatment for Rheumatic Disease. Annals of Internal Medicine, 2005, 143, 20.	2.0	46
157	Inadequate planning and reporting of adjudication committees in clinical trials: Recommendation proposal. Journal of Clinical Epidemiology, 2009, 62, 695-702.	2.4	46
158	Risk of Herpes Zoster in Patients Receiving Anti-TNF- $\hat{l}_{\pm}$ in the Prospective French RATIO Registry. Journal of Investigative Dermatology, 2012, 132, 726-729.	0.3	46
159	Outcome measures for primary Sjögren's syndrome. Journal of Autoimmunity, 2012, 39, 97-102.	3.0	46
160	A home-visiting intervention targeting determinants of infant mental health: the study protocol for the CAPEDP randomized controlled trial in France. BMC Public Health, 2012, 12, 648.	1.2	46
161	Incorporation of assessments of risk of bias of primary studies in systematic reviews of randomised trials: a cross-sectional study. BMJ Open, 2013, 3, e003342.	0.8	46
162	SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ, The, 2020, 368, m122.	3.0	45

#	Article	IF	CITATIONS
163	Impact of Reporting Bias in Network Meta-Analysis of Antidepressant Placebo-Controlled Trials. PLoS ONE, 2012, 7, e35219.	1.1	45
164	Respective Contribution of Chronic Conditions to Disability in France: Results from the National Disability-Health Survey. PLoS ONE, 2012, 7, e44994.	1.1	44
165	The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2016, 43, 1680-1686.	1.0	42
166	Public Availability of Results of Trials Assessing Cancer Drugs in the United States. Journal of Clinical Oncology, 2013, 31, 2998-3003.	0.8	41
167	Peer reviewers identified spin in manuscripts of nonrandomized studies assessing therapeutic interventions, but their impact on spin in abstract conclusions was limited. Journal of Clinical Epidemiology, 2016, 77, 44-51.	2.4	41
168	Impact of a web-based tool (WebCONSORT) to improve the reporting of randomised trials: results of a randomised controlled trial. BMC Medicine, 2016, 14, 199.	2.3	41
169	Reproducibility and sensitivity to change of four scoring methods for the radiological assessment of osteoarthritis of the hand. Annals of the Rheumatic Diseases, 2006, 66, 464-469.	0.5	40
170	Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study. Arthritis Research and Therapy, 2015, 17, 241.	1.6	40
171	Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)- $\hat{l}\pm$ antagonist therapy: safe re-initiation of TNF- $\hat{l}\pm$ blockers after appropriate anti-tuberculous treatment. Clinical Microbiology and Infection, 2008, 14, 183-186.	2.8	39
172	Safety of Surgery After Rituximab Therapy in 133 Patients With Rheumatoid Arthritis: Data From the AutoImmunity and Rituximab Registry. Arthritis Care and Research, 2013, 65, 1874-1879.	1.5	39
173	Bone densitometry in patients with multiple myeloma. American Journal of Medicine, 1992, 93, 595-598.	0.6	38
174	Applicability and generalisability of the results of systematic reviews to public health practice and policy: a systematic review. Trials, 2010, 11, 20.	0.7	38
175	Relation between body mass index, waist circumference, and cardiovascular outcomes in 19,579 diabetic patients with established vascular disease: the REACH Registry. European Journal of Preventive Cardiology, 2012, 19, 241-249.	0.8	38
176	Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort. Journal of Rheumatology, 2013, 40, 1650-1657.	1.0	38
177	Deficiencies in the publication and reporting of the results of systematic reviews presented at scientific medical conferences. Journal of Clinical Epidemiology, 2015, 68, 1488-1495.	2.4	38
178	Development and validation of an instrument to assess treatment adherence for each individual drug taken by a patient. BMJ Open, 2016, 6, e010510.	0.8	38
179	Avoidable waste of research related to outcome planning and reporting in clinical trials. BMC Medicine, 2018, 16, 87.	2.3	38
180	Is My Patient Overwhelmed?. Mayo Clinic Proceedings, 2020, 95, 504-512.	1.4	38

#	Article	IF	CITATIONS
181	Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy. Cancer, 1995, 76, 1559-1563.	2.0	37
182	Mobility decline of unknown origin in mild cognitive impairment: An MRI-based clinical study of the pathogenesis. Brain Research, 2008, 1222, 79-86.	1.1	37
183	Efficacy and Safety of Rituximab in Elderly Patients With Rheumatoid Arthritis Enrolled in a French Society of Rheumatology Registry. Arthritis Care and Research, 2014, 66, 1289-1295.	1.5	37
184	Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. The Cochrane Library, 2014, , CD009036.	1.5	37
185	Incidence, risk factors, and mortality of neonatal and late-onset dilated cardiomyopathy associated with cardiac neonatal lupus. International Journal of Cardiology, 2017, 248, 263-269.	0.8	37
186	Beneficial effects of information leaflets before spinal steroid injection. Joint Bone Spine, 2002, 69, 597-603.	0.8	36
187	Outcome and serum ion determination up to 11 years after implantation of a cemented metal-on-metal hip prosthesis. Monthly Notices of the Royal Astronomical Society: Letters, 2009, 80, 168-173.	1.2	36
188	Systematic review reveals heterogeneity in definition of a clinically relevant difference in pain. Journal of Clinical Epidemiology, 2011, 64, 463-470.	2.4	36
189	Controversy and Debate Series on Core Outcome Sets. Paper 1: Improving the generalizability and credibility of core outcome sets (COS) by a large and international participation of diverse stakeholders. Journal of Clinical Epidemiology, 2020, 125, 206-212.e1.	2.4	36
190	Leukoaraiosis and mobility decline: a high resolution magnetic resonance imaging study in older people with mild cognitive impairment. Neuroscience Letters, 2004, 355, 185-188.	1.0	35
191	Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: Results from a randomized control study. Arthritis and Rheumatism, 2009, 61, 569-576.	6.7	35
192	Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients. Rheumatology, 2019, 58, 401-409.	0.9	35
193	Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies $\hat{a} \in \mathcal{C}$ The Pre-Optimon study. Contemporary Clinical Trials, 2011, 32, 16-24.	0.8	34
194	Misleading abstract conclusions in randomized controlled trials in rheumatology: Comparison of the abstract conclusions and the results section. Joint Bone Spine, 2012, 79, 262-267.	0.8	34
195	An Innovative, Comprehensive Mapping and Multiscale Analysis of Registered Trials for Stem Cell-Based Regenerative Medicine. Stem Cells Translational Medicine, 2016, 5, 826-835.	1.6	34
196	Front-of-Pack Labeling and the Nutritional Quality of Students' Food Purchases: A 3-Arm Randomized Controlled Trial. American Journal of Public Health, 2019, 109, 1122-1129.	1.5	34
197	Participant Informed Consent in Cluster Randomized Trials: Review. PLoS ONE, 2012, 7, e40436.	1.1	34
198	Three randomized controlled trials evaluating the impact of "spin―in health news stories reporting studies of pharmacologic treatments on patients'/caregivers' interpretation of treatment benefit. BMC Medicine, 2019, 17, 105.	2.3	33

#	Article	IF	CITATIONS
199	Future of evidence ecosystem series: 3. From an evidence synthesis ecosystem to an evidence ecosystem. Journal of Clinical Epidemiology, 2020, 123, 153-161.	2.4	33
200	Missing data in randomized controlled trials of rheumatoid arthritis with radiographic outcomes: A simulation study. Arthritis and Rheumatism, 2008, 59, 25-31.	6.7	32
201	Case-Only Designs in Pharmacoepidemiology: A Systematic Review. PLoS ONE, 2012, 7, e49444.	1.1	32
202	Development and Validation of a Questionnaire Assessing Fears and Beliefs of Patients with Knee Osteoarthritis: The Knee Osteoarthritis Fears and Beliefs Questionnaire (KOFBeQ). PLoS ONE, 2013, 8, e53886.	1.1	32
203	Point of data saturation was assessed using resampling methods in a survey with open-ended questions. Journal of Clinical Epidemiology, 2016, 80, 88-96.	2.4	32
204	Patients' perspective on how to improve the care of people with chronic conditions in France: a citizen science study within the ComPaRe e-cohort. BMJ Quality and Safety, 2019, 28, 875-886.	1.8	32
205	Future of evidence ecosystem series: 1. Introduction Evidence synthesis ecosystem needs dramatic change. Journal of Clinical Epidemiology, 2020, 123, 135-142.	2.4	32
206	Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. European Respiratory Journal, 2022, 60, 2102523.	3.1	31
207	Association Between Publication Characteristics and Treatment Effect Estimates. Annals of Internal Medicine, 2018, 169, 385.	2.0	30
208	FROM CLINICAL RECOMMENDATIONS TO MANDATORY PRACTICE The Introduction of Regulatory Practice Guidelines in the French Healthcare System. International Journal of Technology Assessment in Health Care, 2000, 16, 969-975.	0.2	29
209	Antibiotic use: knowledge and perceptions in two university hospitals. Journal of Antimicrobial Chemotherapy, 2011, 66, 936-940.	1.3	29
210	Node-making process in network meta-analysis of nonpharmacological treatment are poorly reported. Journal of Clinical Epidemiology, 2018, 97, 95-102.	2.4	29
211	Changes in total sperm count after gastric bypass and sleeve gastrectomy: the BARIASPERM prospective study. Surgery for Obesity and Related Diseases, 2019, 15, 1271-1279.	1.0	29
212	Live cumulative network meta-analysis: protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptor. BMJ Open, 2016, 6, e011841.	0.8	28
213	Plasma Proteome to Look for Diagnostic Biomarkers of Early Bacterial Sepsis after Liver Transplantation. Anesthesiology, 2010, 112, 926-935.	1.3	28
214	Quality of Reporting of Bioequivalence Trials Comparing Generic to Brand Name Drugs: A Methodological Systematic Review. PLoS ONE, 2011, 6, e23611.	1.1	27
215	Reporting of analyses from randomized controlled trials with multiple arms: a systematic review. BMC Medicine, 2013, 11, 84.	2.3	27
216	Agreement among Healthcare Professionals in Ten European Countries in Diagnosing Case-Vignettes of Surgical-Site Infections. PLoS ONE, 2013, 8, e68618.	1.1	27

#	Article	IF	CITATIONS
217	An Education Program for Risk Factor Management After an Acute Coronary Syndrome. JAMA Internal Medicine, 2014, 174, 40.	2.6	27
218	Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates. The Cochrane Library, 2016, 2016, MR000043.	1.5	27
219	Accuracy in detecting inadequate research reporting by early career peer reviewers using an online CONSORT-based peer-review tool (COBPeer) versus the usual peer-review process: a cross-sectional diagnostic study. BMC Medicine, 2019, 17, 205.	2.3	27
220	Interventions for the prevention and treatment of COVID-19: a living mapping of research and living network meta-analysis. The Cochrane Library, $0$ , $,$ .	1.5	27
221	Serum biologic markers as predictors of disease progression in osteoarthritis of the knee. Arthritis and Rheumatism, 1997, 40, 590-591.	6.7	26
222	The Gap Between Practice and Guidelines in the Choice of First-line Disease Modifying Antirheumatic Drug in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort. Journal of Rheumatology, 2009, 36, 934-942.	1.0	26
223	Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort. Annals of the Rheumatic Diseases, 2012, 71, 1803-1808.	0.5	26
224	Inadequate description of educational interventions in ongoing randomized controlled trials. Trials, 2012, 13, 63.	0.7	26
225	Discordance Between Drug Adherence as Reported by Patients and Drug Importance as Assessed by Physicians. Annals of Family Medicine, 2016, 14, 415-421.	0.9	26
226	COllaborative open platform E-cohorts for research acceleration in trials and epidemiology. Journal of Clinical Epidemiology, 2020, 124, 139-148.	2.4	26
227	Interleukin-1 blocking agents for treating COVID-19. The Cochrane Library, 2022, 2022, CD015308.	1.5	26
228	Factors influencing surgeons' decisions in the indication for total joint replacement in hip osteoarthritis in real life. Arthritis and Rheumatism, 2008, 59, 255-262.	6.7	25
229	Impact of sending email reminders of the legal requirement for posting results on ClinicalTrials.gov: cohort embedded pragmatic randomized controlled trial. BMJ, The, 2014, 349, g5579-g5579.	3.0	25
230	Blockchain, consent and prosent for medical research. Journal of Medical Ethics, 2021, 47, 244-250.	1.0	25
231	Complex systems approach to scientific publication and peer-review system: development of an agent-based model calibrated with empirical journal data. Scientometrics, 2016, 106, 695-715.	1.6	24
232	Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing. Scientific Reports, 2017, 7, 6882.	1.6	24
233	Factors associated with online media attention to research: a cohort study of articles evaluating cancer treatments. Research Integrity and Peer Review, 2017, 2, 9.	2.2	24
234	A Methodologic Systematic Review of Mobile Health Behavior Change Randomized Trials. American Journal of Preventive Medicine, 2019, 57, 836-843.	1.6	24

#	Article	IF	CITATIONS
235	Noninvitation of Eligible Individuals to Participate in Pediatric Studies. JAMA Pediatrics, 2007, 161, 446.	3.6	23
236	Neglected external validity in reports of randomized trials: The example of hip and knee osteoarthritis. Arthritis and Rheumatism, 2009, 61, 361-369.	6.7	23
237	The variability in minimal clinically important difference and patient acceptable symptomatic state values did not have an impact on treatment effect estimates. Journal of Clinical Epidemiology, 2009, 62, 725-728.	2.4	23
238	Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry. Rheumatology, 2014, 53, 1788-1793.	0.9	23
239	Future of evidence ecosystem series: 2. current opportunities and need for better tools and methods. Journal of Clinical Epidemiology, 2020, 123, 143-152.	2.4	23
240	Radiologic progression of hip and knee osteoarthritis. Osteoarthritis and Cartilage, 1999, 7, 222-229.	0.6	22
241	The methods for handling missing data in clinical trials influence sample size requirements. Journal of Clinical Epidemiology, 2004, 57, 447-453.	2.4	22
242	Effect of response format for clinical vignettes on reporting quality of physician practice. BMC Health Services Research, 2009, 9, 128.	0.9	22
243	Influence of vertebral fracture assessment by dual-energy X-ray absorptiometry on decision-making in osteoporosis: a structured vignette survey. Rheumatology, 2011, 50, 2264-2269.	0.9	22
244	A mapping of 115,000 randomized trials revealed a mismatch between research effort and health needs in non–high-income regions. Journal of Clinical Epidemiology, 2018, 98, 123-132.	2.4	22
245	Automatic screening using word embeddings achieved high sensitivity and workload reduction for updating living network meta-analyses. Journal of Clinical Epidemiology, 2019, 108, 86-94.	2.4	22
246	From Clinical Trials to Highly Trustable Clinical Trials: Blockchain in Clinical Trials, a Game Changer for Improving Transparency?. Frontiers in Blockchain, 2019, 2, .	1.6	22
247	A priori postulated and real power in cluster randomized trials: mind the gap. BMC Medical Research Methodology, 2005, 5, 25.	1.4	21
248	Better prioritization to increase research value and decrease waste. BMC Medicine, 2015, 13, 244.	2.3	21
249	Feasibility of individual patient data meta-analyses in orthopaedic surgery. BMC Medicine, 2015, 13, 131.	2.3	21
250	Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data. Rheumatology, 2018, 57, 134-139.	0.9	21
251	Impact of a short version of the CONSORT checklist for peer reviewers to improve the reporting of randomised controlled trials published in biomedical journals: study protocol for a randomised controlled trial. BMJ Open, 2020, 10, e035114.	0.8	21
252	Assessing Complex Emergency Management with Clinical Case-Vignettes: A Validation Study. PLoS ONE, 2015, 10, e0138663.	1.1	21

#	Article	IF	Citations
253	Short-Term Efficacy and Safety of???Leflunomide in the Treatment of???Active Rheumatoid Arthritis in Everyday Clinical Use. Clinical Drug Investigation, 2004, 24, 103-112.	1.1	20
254	Mechanical ventilation and clinical practice heterogeneity in intensive care units: a multicenter case-vignette study. Annals of Intensive Care, 2014, 4, 2.	2.2	20
255	Role of good oral hygiene on clinical evolution of rheumatoid arthritis: a randomized study nested in the ESPOIR cohort. Rheumatology, 2020, 59, 988-996.	0.9	20
256	Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials. Journal of Clinical Epidemiology, 2021, 130, 107-116.	2.4	20
257	Quality of reporting internal and external validity data from randomized controlled trials evaluating stents for percutaneous coronary intervention. BMC Medical Research Methodology, 2009, 9, 24.	1.4	19
258	Do Case Vignettes Accurately Reflect Antibiotic Prescription?. Infection Control and Hospital Epidemiology, 2011, 32, 1003-1009.	1.0	19
259	Quality of reporting of studies evaluating time to diagnosis: a systematic review in paediatrics. Archives of Disease in Childhood, 2014, 99, 244-250.	1.0	19
260	Patients' perspectives on how to decrease the burden of treatment: a qualitative study of HIV care in sub-Saharan Africa. BMJ Quality and Safety, 2019, 28, 266-275.	1.8	19
261	Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants. BMC Medicine, 2012, 10, 142.	2.3	18
262	Interpretation of health news items reported with or without spin: protocol for a prospective meta-analysis of 16 randomised controlled trials. BMJ Open, 2017, 7, e017425.	0.8	18
263	Disagreements in risk of bias assessment for randomised controlled trials included in more than one Cochrane systematic reviews: a research on research study using cross-sectional design. BMJ Open, 2019, 9, e028382.	0.8	18
264	Risk of bias in observational studies using routinely collected data of comparative effectiveness research: a meta-research study. BMC Medicine, 2021, 19, 279.	2.3	18
265	Applicability and generalisability of published results of randomised controlled trials and non-randomised studies evaluating four orthopaedic procedures: methodological systematic review. BMJ: British Medical Journal, 2009, 339, b4538-b4538.	2.4	17
266	Public availability of results of observational studies evaluating an intervention registered at ClinicalTrials.gov. BMC Medicine, 2016, 14, 7.	2.3	17
267	Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. RMD Open, 2019, 5, e000897.	1.8	17
268	Geographical Representativeness of Published and Ongoing Randomized Controlled Trials. The Example of: Tobacco Consumption and HIV Infection. PLoS ONE, 2011, 6, e16878.	1.1	17
269	Clinical and biological assessment of cemented titanium femoral stems: an 11-year experience. International Orthopaedics, 2009, 33, 1209-1215.	0.9	16
270	Translating Cochrane Reviews to Ensure that Healthcare Decision-Making is Informed by High-Quality Research Evidence. PLoS Medicine, 2013, 10, e1001516.	3.9	16

#	Article	IF	Citations
271	Actual management of patients with asymptomatic aortic valve disease: How practice fits with guidelines. American Heart Journal, 2007, 153, 696-703.	1.2	15
272	Data capture by digital pen in clinical trials: A qualitative and quantitative study. Contemporary Clinical Trials, 2008, 29, 314-323.	0.8	15
273	Agreement among Health Care Professionals in Diagnosing Case Vignette-Based Surgical Site Infections. PLoS ONE, 2012, 7, e35131.	1.1	15
274	Outcomes in Registered, Ongoing Randomized Controlled Trials of Patient Education. PLoS ONE, 2012, 7, e42934.	1.1	15
275	LONG-TERM IMPACT OF A RESTRICTIVE LABORATORY TEST ORDERING FORM ON TUMOR MARKER PRESCRIPTIONS. International Journal of Technology Assessment in Health Care, 2003, 19, 106-113.	0.2	14
276	Prospective Evaluation of Inâ€hospital Mortality with the Pâ€POSSUM Scoring System in Patients Undergoing Major Digestive Surgery. World Journal of Surgery, 2012, 36, 2320-2327.	0.8	14
277	Impact of a computer-assisted Screening, Brief Intervention and Referral to Treatment on reducing alcohol consumption among patients with hazardous drinking disorder in hospital emergency departments. The randomized BREVALCO trial. Drug and Alcohol Dependence, 2016, 165, 236-244.	1.6	14
278	Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the $\hat{a} \in \mathbb{C} RA\hat{a} \in \mathbb{C} M$ registry. RMD Open, 2017, 3, e000515.	1.8	14
279	How to perform a critical analysis of a randomised controlled trial. Best Practice and Research in Clinical Rheumatology, 2009, 23, 291-303.	1.4	13
280	Classification systems to improve assessment of risk of bias. Journal of Clinical Epidemiology, 2012, 65, 236-238.	2.4	13
281	A test for reporting bias in trial networks: simulation and case studies. BMC Medical Research Methodology, 2014, 14, 112.	1.4	13
282	Reporting funding source or conflict of interest in abstracts of randomized controlled trials, no evidence of a large impact on general practitioners $\hat{a} \in \mathbb{T}$ confidence in conclusions, a three-arm randomized controlled trial. BMC Medicine, 2014, 12, 69.	2.3	13
283	Reporting studies on time to diagnosis: proposal of a guideline by an international panel (REST). BMC Medicine, 2016, 14, 146.	2.3	13
284	Characteristics and Public Availability of Results of Clinical Trials on Rare Diseases Registered at Clinicaltrials.gov. JAMA Internal Medicine, 2016, 176, 556.	2.6	13
285	Systematic reviews of therapeutic interventions frequently consider patient-important outcomes. Journal of Clinical Epidemiology, 2017, 84, 70-77.	2.4	13
286	A scoping review provided a framework for new ways of doing research through mobilizing collective intelligence. Journal of Clinical Epidemiology, 2019, 110, 1-11.	2.4	13
287	Living network meta-analysis was feasible when considering the pace of evidence generation. Journal of Clinical Epidemiology, 2019, 108, 10-16.	2.4	13
288	Use of wearable biometric monitoring devices to measure outcomes in randomized clinical trials: a methodological systematic review. BMC Medicine, 2020, 18, 310.	2.3	13

#	Article	IF	Citations
289	Adverse Events Associated with Rofecoxib Therapy. Drug Safety, 2003, 26, 49-54.	1.4	12
290	Reporting of radiographic methods in randomised controlled trials assessing structural outcomes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 66, 651-657.	0.5	12
291	Knee Arthroplasty: Disabilities in Comparison to the General Population and to Hip Arthroplasty Using a French National Longitudinal Survey. PLoS ONE, 2008, 3, e2561.	1.1	12
292	Meta-Analysis of a Complex Network of Non-Pharmacological Interventions: The Example of Femoral Neck Fracture. PLoS ONE, 2016, 11, e0146336.	1.1	12
293	Short-Term Efficacy of Rofecoxib and Diclofenac in Acute Shoulder Pain: A Placebo-Controlled Randomized Trial. PLOS Clinical Trials, 2007, 2, e9.	3.5	11
294	Evolution of disability in adults with hip arthroplasty: A national longitudinal study. Arthritis and Rheumatism, 2007, 57, 364-371.	6.7	11
295	Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention. Trials, 2009, 10, 29.	0.7	11
296	Making protocols available with the article improved evaluation of selective outcome reporting. Journal of Clinical Epidemiology, 2018, 104, 95-102.	2.4	11
297	Designs of trials assessing interventions to improve the peer review process: a vignette-based survey. BMC Medicine, 2018, 16, 191.	2.3	11
298	Evaluation of Patient Willingness to Adopt Remote Digital Monitoring for Diabetes Management. JAMA Network Open, 2021, 4, e2033115.	2.8	11
299	Primer: assessing the efficacy and safety of nonpharmacologic treatments for chronic rheumatic diseases. Nature Clinical Practice Rheumatology, 2006, 2, 313-319.	3.2	10
300	Methodological issues in trials assessing primary prophylaxis of venous thrombo-embolism. European Heart Journal, 2006, 27, 227-236.	1.0	10
301	Elaboration and validation of a questionnaire assessing patient expectations about management of knee osteoarthritis by their physicians: the Knee Osteoarthritis Expectations Questionnaire. Annals of the Rheumatic Diseases, 2013, 72, 552-559.	0.5	10
302	Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry. Rheumatology, 2017, 56, kew476.	0.9	10
303	Published randomized trials performed in Sub-Saharan Africa focus on high-burden diseases but are frequently funded and led by high-income countries. Journal of Clinical Epidemiology, 2017, 82, 29-36.e6.	2.4	10
304	Predischarge C-Reactive Protein and 1-year Outcome After Acute Coronary Syndromes. American Journal of Medicine, 2006, 119, 684-692.	0.6	9
305	Development and Evaluation of a Pedagogical Tool to Improve Understanding of a Quality Checklist: A Randomised Controlled Trial. PLOS Clinical Trials, 2007, 2, e22.	3.5	9
306	Monitoring of bone turnover markers does not improve persistence with ibandronate treatment. Joint Bone Spine, 2012, 79, 389-392.	0.8	9

#	Article	IF	Citations
307	Commentary: Meta-epidemiology, meta-meta-epidemiology or network meta-epidemiology?. International Journal of Epidemiology, 2013, 42, 1131-1133.	0.9	9
308	Automatic classification of registered clinical trials towards the Global Burden of Diseases taxonomy of diseases and injuries. BMC Bioinformatics, 2016, 17, 392.	1.2	9
309	A protocol of a cross-sectional study evaluating an online tool for early career peer reviewers assessing reports of randomised controlled trials. BMJ Open, 2017, 7, e017462.	0.8	9
310	Avoidable waste related to inadequate methods and incomplete reporting of interventions: a systematic review of randomized trials performed in Sub-Saharan Africa. Trials, 2017, 18, 291.	0.7	9
311	Protocol for a systematic review of N-of-1 trial protocol guidelines and protocol reporting guidelines. Systematic Reviews, 2017, 6, 132.	2.5	9
312	Identification of Patient Perceptions That Can Affect the Uptake of Interventions Using Biometric Monitoring Devices: Systematic Review of Randomized Controlled Trials. Journal of Medical Internet Research, 2020, 22, e18986.	2.1	9
313	Designing Randomized-Controlled Trials to Improve Head-Louse Treatment: Systematic Review Using a Vignette-Based Method. Journal of Investigative Dermatology, 2014, 134, 628-634.	0.3	8
314	Latent Tuberculosis Infection Screening and 2-Year Outcome in Antiretroviral-Naive HIV-Infected Patients in a Low-Prevalence Country. Annals of the American Thoracic Society, 2015, 12, 150727131311009.	1.5	8
315	Anticovid, a comprehensive open-access real-time platform of registered clinical studies for COVID-19. Journal of Antimicrobial Chemotherapy, 2020, 75, 2708-2710.	1.3	8
316	Social and personal consequences of disability in adults with hip and knee arthroplasty. A French national community based survey. Journal of Rheumatology, 2004, 31, 759-66.	1.0	8
317	Methods to Generate Innovative Research Ideas and Improve Patient and Public Involvement in Modern Epidemiological Research: Review, Patient Viewpoint, and Guidelines for Implementation of a Digital Cohort Study. Journal of Medical Internet Research, 2021, 23, e25743.	2.1	8
318	From Clinical Guidelines to Quality Assurance: the Experience of Assistance Publique-HÃ"pitaux de Paris. International Journal for Quality in Health Care, 1997, 9, 215-219.	0.9	7
319	Methodology ofÂtherapeutic trials: lessons from theÂlate evidence ofÂtheÂcardiovascular toxicity ofÂsomeÂcoxibs. Joint Bone Spine, 2005, 72, 451-455.	0.8	7
320	Smoking motivations and quitting motivations among HIV-infected smokers. Antiviral Therapy, 2009, 14, 781-787.	0.6	7
321	Delphi-Consensus Weights for Ischemic and Bleeding Events to Be Included in a Composite Outcome for RCTs in Thrombosis Prevention. PLoS ONE, 2011, 6, e18461.	1.1	7
322	Bacteremia in patients receiving TNF-alpha antagonists – A prospective multicenter study. Journal of Infection, 2013, 67, 524-528.	1.7	7
323	Comparison of Estimates between Cohort and Case–Control Studies in Meta-Analyses of Therapeutic Interventions: A Meta-Epidemiological Study. PLoS ONE, 2016, 11, e0154877.	1.1	7
324	Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis. Arthritis Research and Therapy, 2018, 20, 122.	1.6	7

#	Article	IF	CITATIONS
325	Consolidated Standards of Reporting Trials (CONSORT) extensions covered most types of randomized controlled trials, but the potential workload for authors was high. Journal of Clinical Epidemiology, 2019, 113, 168-175.	2.4	6
326	Artificial intelligence in health care: value for whom?. The Lancet Digital Health, 2020, 2, e338-e339.	5.9	6
327	The VEPRO trial: A cross-over randomised controlled trial comparing 2 progressive lenses for patients with presbyopia. Trials, 2008, 9, 54.	0.7	5
328	Reporting of corticosteroid use in systemic disease trials: Evidence from a systematic review of the potential impact on treatment effect. Arthritis Care and Research, 2010, 62, 1002-1008.	1.5	5
329	Impact of adding a limitations section to abstracts of systematic reviews on readers' interpretation: a randomized controlled trial. BMC Medical Research Methodology, 2014, 14, 123.	1.4	5
330	Reporting of statistically significant results at ClinicalTrials.gov for completed superiority randomized controlled trials. BMC Medicine, 2016, 14, 192.	2.3	5
331	Inadequate critical appraisal of studies in systematic reviews of time to diagnosis. Journal of Clinical Epidemiology, 2016, 78, 43-51.	2.4	5
332	Dosage of Preventive or Therapeutic Exercise Interventions: Review of Published Randomized Controlled Trials and Survey of Authors. Archives of Physical Medicine and Rehabilitation, 2017, 98, 2558-2565.e10.	0.5	5
333	Variation in severe postpartum hemorrhage management: A national vignette-based study. PLoS ONE, 2018, 13, e0209074.	1.1	5
334	Power behind the throne: A clinical trial simulation study evaluating the impact of controllable design factors on the power of antidepressant trials. International Journal of Methods in Psychiatric Research, 2019, 28, e1779.	1.1	5
335	An International, Mixed-Methods Study of the Perceived Intrusiveness of Remote Digital Diabetes Monitoring. Mayo Clinic Proceedings, 2021, 96, 1236-1247.	1.4	5
336	Comparison of Treatment Effect Estimates for Pharmacological Randomized Controlled Trials Enrolling Older Adults Only and Those including Adults: A Meta-Epidemiological Study. PLoS ONE, 2013, 8, e63677.	1.1	5
337	Timing of publication of abstracts of randomized controlled trials presented in congresses: The example of the European League against Rheumatism meeting. Joint Bone Spine, 2018, 85, 109-114.	0.8	4
338	Potential of Stratified Medicine for High Blood Pressure Management. Hypertension, 2019, 74, 1420-1427.	1.3	4
339	Baseline Characteristics of a National French E-Cohort of Hidradenitis Suppurativa in ComPaRe and Comparison with Other Large Hidradenitis Suppurativa Cohorts. Dermatology, 2021, 237, 748-758.	0.9	4
340	A classification of methods used to personalize participative interventions revealed inadequate reporting in trial protocols. Journal of Clinical Epidemiology, 2021, 133, 80-93.	2.4	4
341	Overcoming Barriers to Mobilizing Collective Intelligence in Research: Qualitative Study of Researchers With Experience of Collective Intelligence. Journal of Medical Internet Research, 2019, 21, e13792.	2.1	4
342	Preferences for Alternative Care Modalities Among French Adults With Chronic Illness. JAMA Network Open, 2021, 4, e2141233.	2.8	4

#	Article	IF	CITATIONS
343	Increasing the evidence base in journalology: creating an international best practice journal research network. BMC Medicine, 2016, 14, 154.	2.3	3
344	Control treatments in biologics trials of rheumatoid arthritis were often not deemed acceptable in the context of care. Journal of Clinical Epidemiology, 2016, 69, 235-244.	2.4	3
345	Ten Years of Interventional Research in Systemic Sclerosis: A Systematic Mapping of Trial Registries. Arthritis Care and Research, 2020, 72, 140-148.	1.5	3
346	Patients' Perspectives on Transforming Clinical Trial Participation: Large Online Vignette-based Survey. Journal of Medical Internet Research, 2022, 24, e29691.	2.1	3
347	Cost-effectiveness analysis of strategies using new immunological diagnostic tests of latent tuberculosis infection before TNF-blockers therapy. Presse Medicale, 2018, 47, e9-e13.	0.8	2
348	Acceptable medication non-adherence: A crowdsourcing study among French physicians for commonly prescribed medications. PLoS ONE, 2018, 13, e0209023.	1.1	2
349	Vitiligo Treatment Impact score (VITs): development and validation of a vitiligo burden of treatment questionnaire using the ComPaRe Vitiligo eâ€cohort. Journal of the European Academy of Dermatology and Venereology, 2021, 36, 279.	1.3	2
350	Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry. Joint Bone Spine, 2022, 89, 105310.	0.8	2
351	Effets bénéfiques de l'utilisation d'une notice d'information avant une injection rachidienne de dérivé cortisonique. Revue Du Rhumatisme (Edition Francaise), 2002, 69, 1235-1242.	0.0	1
352	Premature Application of Trial Results to Clinical Practice. JAMA - Journal of the American Medical Association, 2003, 290, 3072.	3.8	1
353	Do hip OA patients referred to orthopedic surgeons by general practitioners and rheumatologists differ?. Clinical Rheumatology, 2012, 31, 1301-1307.	1.0	1
354	Reply to W. Read. Journal of Clinical Oncology, 2014, 32, 603-604.	0.8	1
355	Dissemination of 2014 dual antiplatelet therapy (DAPT) trial results: a systematic review of scholarly and media attention over 7 months. BMJ Open, 2017, 7, e014503.	0.8	1
356	Controversy and Debate Series on Core Outcome Sets. Paper 7: Response to comments on the paper 2-6 re "Improving the generalizability and credibility of Core Outcome Sets (COSs) by involving large international sample of participants†Journal of Clinical Epidemiology, 2020, 125, 232-234.	2.4	1
357	External factors may influence Cochrane reviewers when classifying the risk of bias of original reports. Journal of Clinical Epidemiology, 2020, 123, 1-8.	2.4	1
358	Tocilizumab in Treatment for Patients With COVID-19â€"Reply. JAMA Internal Medicine, 2021, 181, 1020-1021.	2.6	1
359	Inappropriateness of randomised trials for complex phenomena. BMJ: British Medical Journal, 2005, 330, 94.2.	2.4	1
360	ASSIST Applicability Scoring of Surgical trials. An Investigator-reported aSsessment Tool. PLoS ONE, 2012, 7, e42258.	1.1	1

#	Article	IF	CITATIONS
361	Acceptability of and Willingness to Take Digital Pills by Patients, the Public, and Health Care Professionals: Qualitative Content Analysis of a Large Online Survey. Journal of Medical Internet Research, 2022, 24, e25597.	2.1	1
362	Assessment of transparency and selective reporting of interventional trials studying colorectal cancer. BMC Cancer, 2022, 22, 278.	1.1	1
363	Toward an observatory of the evolution of clinical trials through phylomemy reconstruction: the COVID-19 vaccines example. Journal of Clinical Epidemiology, 2022, , .	2.4	1
364	La surveillance des marqueurs du remodelage osseux n'améliore pas la persistance au traitement par ibandronate. Revue Du Rhumatisme (Edition Francaise), 2012, 79, 68-72.	0.0	0
365	Conclusions erronées des résumés dans les essais cliniques contrÃ1és en rhumatologieÂ: comparaisons entre les conclusions et la partie résultats des résumés. Revue Du Rhumatisme (Edition) Tj I	ETQøl 1 (	).7 <b>8</b> 4314 rgB
366	Reply to Letter. Annals of Surgery, 2015, 262, e67-e69.	2.1	0
367	Délai de publication des résumés des essais contrÃ1és randomisés présentés en congrèsÂ; l' congrès de la ligue européenne contre le rhumatisme (EULAR). Revue Du Rhumatisme (Edition) Tj ETQq1 1 0		
368	Inadequate reporting of concomitant medications in rheumatology randomized controlled trials of pharmacologic interventions. Seminars in Arthritis and Rheumatism, 2019, 49, 453-458.	1.6	0
369	Closing the Gap between Diagnostic Test Accuracy Reviews and Reporting Guidelines: The PRISMA-Diagnostic Test Accuracy Statement. Clinical Chemistry, 2019, 65, 222-224.	1.5	0
370	Looking into the Future—The EULAR Disease Activity Scores: Toward a Consensual Evaluation of Primary Sjogren's Syndrome. , 2011, , 443-454.		0
371	Blockchain for increased trust in observational studies. The Lancet Digital Health, 2021, 3, e762.	5.9	0
372	Availability of results of interventional studies assessing colorectal cancer from 2013 to 2020. PLoS ONE, 2022, 17, e0266496.	1.1	0
373	Title is missing!. , 2020, 15, e0237296.		0
374	Title is missing!. , 2020, 15, e0237296.		0
375	Title is missing!. , 2020, 15, e0237296.		0
376	Title is missing!. , 2020, 15, e0237296.		0
377	Title is missing!. , 2020, 15, e0237296.		0
378	Title is missing!. , 2020, 15, e0237296.		0